NeuroRx Wins Startup Competition at IATI-Biomed 2016, Israel’s Leading Life Science ConferenceMay. 29, 2016
IATI-BIOMED 2016 announced today that NeuroRx won IATI-BIOMED’s startup competition and was chosen out of dozens of applicants as the most innovative life science company. The prize was awarded to Dr. Jonathan Javitt, Founder and CEO of NeuroRx, by Ruti Alon, IATI-Biomed Co-Chairperson and General Partner, Pitango Venture Capital, at the closing session of the conference.
NeuroRx, Inc. has successfully completed a Phase 2 for a newly-purposed class of drugs that have shown rapid efficacy in reducing symptoms of depression and risk of suicide. The drug named Cuclurad targets the brain’s NMDA receptor rather than the traditional serotonin pathway. It includes initial use of Ketamine, followed by D-cycloserine in combination with one of three FDA-approved mood stabilizers and achieves reduction of symptoms within two hours of treatment and maintains that clinical benefit over 8 weeks. The Company is expected to receive FDA approval under a fast track, following completion of clinical trials expected by the end of 2017.
Anti-suicide drug wins praise at IATI-Biomed 2016 - Israel21c.